Cargando…
Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs
Liver-type fatty acid-binding protein (L-FABP) is a biomarker for the early detection of renal diseases in humans. L-FABP is a cytotoxic oxidation product secreted from the proximal tubules under ischemic and oxidative stress conditions. First, L-FABP gene expression in the kidney and liver was eval...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Veterinary Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498833/ https://www.ncbi.nlm.nih.gov/pubmed/34526412 http://dx.doi.org/10.1292/jvms.20-0698 |
_version_ | 1784580254425153536 |
---|---|
author | TAKASHIMA, Satoshi NAGAMORI, Yumiko OHATA, Keiichi OIKAWA, Tsuyoshi SUGAYA, Takeshi KOBATAKE, Yui NISHII, Naohito |
author_facet | TAKASHIMA, Satoshi NAGAMORI, Yumiko OHATA, Keiichi OIKAWA, Tsuyoshi SUGAYA, Takeshi KOBATAKE, Yui NISHII, Naohito |
author_sort | TAKASHIMA, Satoshi |
collection | PubMed |
description | Liver-type fatty acid-binding protein (L-FABP) is a biomarker for the early detection of renal diseases in humans. L-FABP is a cytotoxic oxidation product secreted from the proximal tubules under ischemic and oxidative stress conditions. First, L-FABP gene expression in the kidney and liver was evaluated. Next, the urinary L-FABP concentrations in dogs with or without renal diseases were measured using a novel enzyme-linked immunosorbent assay kit. Urinary L-FABP was normalized relative to urinary creatinine (uCre) concentrations (µg/g uCre). Finally, the relationships between urinary L-FABP and renal biomarkers used in canine medicine or serum alanine transaminase (ALT) as an indicator of liver damage were examined. Serum and urine samples from 94 client-owned dogs including 23 dogs with renal diseases and 71 dogs without renal diseases were used for analysis. Relative L-FABP gene expression was confirmed both in the liver and kidney. Dogs with renal diseases had a significantly higher urinary L-FABP than those without, and its predictive cutoff value was 26 µg/g uCre. Urinary L-FABP was significantly correlated with serum creatinine (r=0.4674, P<0.01), urea nitrogen (r=0.4907, P<0.01), urine specific gravity (r=−0.5100, P<0.01), and urine protein/creatinine ratio (r=0.7216, P<0.01), but not with serum ALT. Hence, dogs with a high urinary L-FABP value were more likely to have renal diseases. |
format | Online Article Text |
id | pubmed-8498833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Japanese Society of Veterinary Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84988332021-10-13 Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs TAKASHIMA, Satoshi NAGAMORI, Yumiko OHATA, Keiichi OIKAWA, Tsuyoshi SUGAYA, Takeshi KOBATAKE, Yui NISHII, Naohito J Vet Med Sci Internal Medicine Liver-type fatty acid-binding protein (L-FABP) is a biomarker for the early detection of renal diseases in humans. L-FABP is a cytotoxic oxidation product secreted from the proximal tubules under ischemic and oxidative stress conditions. First, L-FABP gene expression in the kidney and liver was evaluated. Next, the urinary L-FABP concentrations in dogs with or without renal diseases were measured using a novel enzyme-linked immunosorbent assay kit. Urinary L-FABP was normalized relative to urinary creatinine (uCre) concentrations (µg/g uCre). Finally, the relationships between urinary L-FABP and renal biomarkers used in canine medicine or serum alanine transaminase (ALT) as an indicator of liver damage were examined. Serum and urine samples from 94 client-owned dogs including 23 dogs with renal diseases and 71 dogs without renal diseases were used for analysis. Relative L-FABP gene expression was confirmed both in the liver and kidney. Dogs with renal diseases had a significantly higher urinary L-FABP than those without, and its predictive cutoff value was 26 µg/g uCre. Urinary L-FABP was significantly correlated with serum creatinine (r=0.4674, P<0.01), urea nitrogen (r=0.4907, P<0.01), urine specific gravity (r=−0.5100, P<0.01), and urine protein/creatinine ratio (r=0.7216, P<0.01), but not with serum ALT. Hence, dogs with a high urinary L-FABP value were more likely to have renal diseases. The Japanese Society of Veterinary Science 2021-09-14 2021-09 /pmc/articles/PMC8498833/ /pubmed/34526412 http://dx.doi.org/10.1292/jvms.20-0698 Text en ©2021 The Japanese Society of Veterinary Science https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Internal Medicine TAKASHIMA, Satoshi NAGAMORI, Yumiko OHATA, Keiichi OIKAWA, Tsuyoshi SUGAYA, Takeshi KOBATAKE, Yui NISHII, Naohito Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs |
title | Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs |
title_full | Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs |
title_fullStr | Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs |
title_full_unstemmed | Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs |
title_short | Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs |
title_sort | clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498833/ https://www.ncbi.nlm.nih.gov/pubmed/34526412 http://dx.doi.org/10.1292/jvms.20-0698 |
work_keys_str_mv | AT takashimasatoshi clinicalevaluationofurinarylivertypefattyacidbindingproteinforthediagnosisofrenaldiseasesindogs AT nagamoriyumiko clinicalevaluationofurinarylivertypefattyacidbindingproteinforthediagnosisofrenaldiseasesindogs AT ohatakeiichi clinicalevaluationofurinarylivertypefattyacidbindingproteinforthediagnosisofrenaldiseasesindogs AT oikawatsuyoshi clinicalevaluationofurinarylivertypefattyacidbindingproteinforthediagnosisofrenaldiseasesindogs AT sugayatakeshi clinicalevaluationofurinarylivertypefattyacidbindingproteinforthediagnosisofrenaldiseasesindogs AT kobatakeyui clinicalevaluationofurinarylivertypefattyacidbindingproteinforthediagnosisofrenaldiseasesindogs AT nishiinaohito clinicalevaluationofurinarylivertypefattyacidbindingproteinforthediagnosisofrenaldiseasesindogs |